Tag Archives: cardiovascular outcomes

Peripheral artery disease (PAD) affects millions of people with type 2 diabetes worldwide, increasing the risk of cardiovascular events and limb loss. With recent research into incretin‑based therapies, particularly glucagon‑like peptide‑1 receptor agonists (GLP‑1s), clinicians are asking whether these drugs can improve outcomes in PAD patients treated with GLP‑1s, beyond …

The GLP‑1 mechanism of action is more than a tool for lowering glucose—it’s a central player in a complex system influencing body weight, cardiovascular outcomes, liver health, and possibly even brain function. As GLP‑1 receptor agonists become more widely prescribed, understanding how this pathway works helps clinicians better tailor treatments …